James F. Reddoch, EVP, Research & Investments at Royalty Pharma plc (RPRX), sold 200,000 shares at $46.89 ($9.4M) on 2021-03-02, disclosed to the SEC on 2021-03-04.
Open-market sale of $9.4M RPRX by EVP, Research & Investments. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $46.89 | 96,490 | $4.5M | 48.2% |
| 2 | $46.89 | 96,490 | $4.5M | 48.2% |
| 3 | $47.84 | 3,510 | $168K | 1.8% |
| 4 | $47.84 | 3,510 | $168K | 1.8% |
| Total | $46.92 avg | 200,000 | $9.4M | 100% |
| Filing → |
| RPRX | SELL | 2022-05-31 | $3.1M | — | Filing → |
| RPRX | SELL | 2022-05-23 | $3.0M | — | Filing → |
| RPRX | SELL | 2021-07-27 | $712K | — | Filing → |